Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1759-1771

  Cambridge, Chino D ^a   Singh, Shree R ^a   Waffo, Alain B ^a   Fairley, Stacie J ^a   Dennis, Vida A ^a  

^a ALABAMA STATE UNIVERSITY   (United States)

Author keywords

Bacteria; Chitosan; Chlamydia trachomatis; DNA; MOMP; Vaccine

Indexed keywords

CHITOSAN; DNA VACCINE; MAJOR OUTER MEMBRANE PROTEIN; NANOPARTICLE; OUTER MEMBRANE PROTEIN; RECOMBINANT MAJOR OUTER MEMBRANE PROTEIN CHLAMYDIA TRACHOMATIS DNA VACCINE; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN COS7; CHLAMYDIA TRACHOMATIS; COACERVATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; ENZYMATIC DEGRADATION; FEMALE; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; INFRARED SPECTROSCOPY; LEG MUSCLE; MORPHOLOGY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SCANNING ELECTRON MICROSCOPY; SPLEEN; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROSCOPY; WESTERN BLOTTING; ZETA POTENTIAL;

BACTERIA; CHITOSAN; CHLAMYDIA TRACHOMATIS; DNA; MOMP; VACCINE;

ANIMALS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CHITOSAN; CHLAMYDIA TRACHOMATIS; COS CELLS; DNA, BACTERIAL; DRUG CARRIERS; DRUG STABILITY; FEMALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; PORINS; RNA; VACCINES, DNA;

EID: 84877723574     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S42723     Document Type: Article

References (50)

1. World Health Organization. Global Prevalence and Incidence of Selected Sexually Transmitted Diseases: Overviews and Estimates. Geneva, Switzerland: World Health Organization; 1996:1-52.
2. World Health Organization. DoRHaR, Prevalence and Incidence of Selected Sexually Transmitted Infections. Geneva, Switzerland: World Health Organization; 2011.
3. Westrom LJR, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis. 1992;4:185-192.
4. Plummer FA, Simonsen JN, Cameron SJ, Ndinya-Achola JO, Kreiss JK, Gakinya NM. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1991;6:1236-1237.
5. Beagley KW, Timms P. Chlamydia trachomatis infection: incidence, health costs and prospects for vaccine development. J Reprod Immunol. 2000;48:47-68.
6. Karunakaran KP, Yu H, Foster LJ, Brunham RC. Development of a Chlamydia trachomatis T cell vaccine. Hum Vaccine. 2010;6:676-680.
7. Caldwell D, Kromhout J, Schachter J. Purif ication and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun. 1981;31:1161-1176.
8. Coler RN, Bhatia A, Maisonneuve JF, et al. Identif ication and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis. FEMS Immunol Med Microbiol. 2009;55:258-270.
9. Singh SR, Hulett K, Pillai SR, Dennis VA, Oh MK, Scissum-Gunn K. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection. Vaccine. 2006;24:1213-1224.
10. Ortiz L, Angevine M, Kim SK, Watkins D, DeMars R. T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar-specific immune responses in infected humans. Infect Immun. 2000;68:1719-1723.
11. Stagg AJ, Elsley WA, Pickett MA, Ward ME, Knight SC. Primary human T-cell responses to the major outer membrane protein of Chlamydia trachomatis. Immunology. 1993;79:1-9.
12. Zhu S, Chen J, Zheng M, Gong W, Xue X, Li W. Identification of immunodominant linear B-cell epitopes within the major outer membrane protein of Chlamydia trachomatis. Acta Biochim Biophys Sin. 2010;42:8.
13. Xu W, Liu J, Gong W, Chen J, Zhu S, Zhang L. Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1. Vaccine. 2011;29:2672-2678.
14. Pal S, Peterson EM, de la Maza LM. Vaccination with the Chlamydiatrachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun. 2005;73:8153-8160.
15. Sun G, Pal S, Weiland J, Peterson EM, de la Maza LM. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine. 2009;27:5020-5025.
16. Eko FO, He Q, Brown T, et al. A novel recombinant multi-subunit vaccine against Chlamydia. J Immunol. 2004;173:3375-3382.
17. Dai C, Wang B. Microencapsulation peptide and protein drugs delivery system. Colloid Surf B Biointerfaces. 2005;41:117-120.
18. Tyagi RK, Garg NK, Sahu T. Vaccination strategies against malaria: novel carrier(s) more than a tour de force. J Control Release. 2012;162: 242-254.
19. Kathuria N, Kraynyak KA, Carnathan D, Betts M, Weiner DB, Kutzler MA. Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 Chemokine Immunoadjuvant. Hum Vaccin Immunother. 2012:8;1607-1619.
20. Childs TS, Webley WC. In vitro assessment of halobacterial gas vesicles as a Chlamydia vaccine display and delivery system. Vaccine. 2012;30: 5942-5948.
21. Boyoglu S, Vig K, Pillai S, Rangari V, Dennis VA, Khazi F. Enhanced delivery and expression of a nanoencapsulated DNA vaccine vector for respiratory syncytial virus. Nanomedicine. 2009;5: 463-472.
22. Tyagi RK, Sharma PK, Vyas SP, Mehta A. Various carrier system(s) mediated genetic vaccination strategies against malaria. Expert Rev Vaccines. 2008;7:499-520. Retraction in Expert Rev Vaccines. 2011;10:1244.
23. Taha MA, Singh SR, Dennis VA. Biodegradable PLGA85/15 nanoparticles as a delivery vehicle for Chlamydia trachomatis recombinant MOMP-187 peptide. Nanotechnology. 2012;23:325101.
24. Felt O, Buri P, Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm. 1998;24:979-993.
25. MacLaughlin FC, Mumper RJ, Wang J. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Controlled Rel. 1998;56:259-272.
26. Mao S, Shuai X, Unger F, Simon M. The depolymerization of chitosan: effects on physiochemical and biological properties. Int J Pharm. 2004;281:45-54.
27. Gan Q, Wang T, Cochrane C, McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces. 2005;44:65-73.
28. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev. 2001;47:83-97.
29. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res. 1994;11:1358-1361.
30. Gan Q, Wang T. Chitosan nanoparticles as protein delivery carrier-Systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerfaces. 2007;59:24-34.
31. Sun Y, Zhang S, Peng X, et al. Preparation, characterization and transfection efficacy of chitosan nanoparticles containing the intestinal trefoil factor gene. Mol Biol Rep. 2012;39:945-952.
32. Yu-Hong L, Min-Wen F, Zhi C, Qi Z, Hai-Rui Y. Chitosan-DNA microparticles as mucosal delivery system: synthesis, characterization and release in vitro. Chin Med. 2005;118:936-941.
33. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissues. Adv Drug Deliv Rev. 2003;55: 329-347.
34. Ravi Kumar MN, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;25:1771-1777.
35. Bozkir A, Saka OM. Chitosan-DNA nanoparticles: effect on DNA integrity, bacterial transformation and transfection efficiency. J Drug Target. 2004;12:281-288.
36. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release. 2001;70:399-421.
37. Borchard G. Chitosans for gene delivery. Adv Drug Deliv Rev. 2001;52: 145-150.
38. Zhao K, Shi X, Zhao Y, et al. Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles. Vaccine. 2011;29:8549-8556.
39. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release. 2003;89:151-165.
40. Hu Y, Jiang X, Ding Y, Ge H, Yuan Y, Yang C. Synthesis and characterization of chitosan-poly(acrylic acid) nanoparticles. Biomaterials. 2002;23:3193-3201.
41. Köping-Höggård M, Tubulekas I, Guan H, Edwards K, Nilsson M, Vårum KM. Chitosan as a non-viral gene delivery system. Structureproperty relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther. 2001;8:1108-1121.
42. Waeckerle-Men Y, Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev. 2005;57:475-482.
43. Waeckerle-Men Y, Allmen EU, Gander B, et al. Encapsulation of proteins and peptides into biodegradable poly(d,l-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine. 2006;24:1847-1857.
44. Guerra GD, Cerrai P, Tricoli M, Maltini S, del Guerra RS. In-vitro cytotoxicity testing of chitosan-containing polyelectrolyte complexes. J Mater Sci Mater Med. 1998;9:73-76.
45. Mumper RJ, Claspell JM, Rolland AP. Novel polymeric condensing carriers for gene delivery. Proc Natl Acad Sci U S A. 1995;22: 178-179.
46. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev. 2001;51:81-96.
47. Vinogradov SV, Kabanov AV. Nanosized cationic hyrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev. 2002;54:135-147.
48. Hsu SH, Ho TT, Tseng TC. Nanoparticle uptake and gene transfer efficiency for MSCs on chitosan and chitosan-hyaluronan substrates. Biomaterials. 2012;33:3639-3650.
49. Saka OM, Bozkir A. Formulation and in vitro characterization of PEGylated chitosan and polyethylene imine polymers with thrombospondin-I gene bearing pDNA. J Biomed Mater Res B Appl Biomater. 2012;100:984-992.
50. Jean M, Alameh M, Buschmann MD, Merzouki A. Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes. Gene Ther. 2011;18:807-816.